Class Switch Recombination and Somatic Hypermutation in Early Mouse B Cells Are Mediated by B Cell and Toll-like Receptors

Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York, United States
Immunity (Impact Factor: 21.56). 08/2007; 27(1):64-75. DOI: 10.1016/j.immuni.2007.05.018
Source: PubMed


Activation-induced cytidine deaminase (AID) is required for immunoglobulin (Ig) gene class switch recombination (CSR), somatic hypermutation (SHM), and somatic hyperconversion. In general, high AID expression is found in mature B cells that are responding to antigens. However, AID expression and SHM have also been detected in developing B cells from transgenic mice that have a limited Ig repertoire. Here we demonstrate that AID expression, ongoing CSR, and active SHM occur in developing B cells from wild-type mice. Further, our results suggest that somatic variants arising from developing B cells in the bone marrow further diversify in the spleen of unimmunized mice. AID expression in developing B cells is T cell independent but involves engagement of B cell receptors and Toll-like receptors. Early AID expression can increase the preimmune repertoire of developing B cells, may provide an innate population of IgG- and IgA-expressing cells, and could be involved in receptor editing of self-reactive immature B cells.

Download full-text


Available from: Thereza Imanishi-Kari
  • Source
    • "Although physiological AID expression is largely restricted to mature B cells, its expression has also been reported in other settings. AID is expressed in developing B cells in the bone marrow, inducing robust CSR to a subset of isotypes (31, 32). The physiological relevance of CSR in the bone marrow is not clear at present. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Secondary diversification of the antibody repertoire upon antigenic challenge, in the form of immunoglobulin heavy chain (IgH) class-switch recombination (CSR) endows mature, naïve B cells in peripheral lymphoid organs with a limitless ability to mount an optimal humoral immune response, thus expediting pathogen elimination. CSR replaces the default constant (CH) region exons (Cμ) of IgH with any of the downstream CH exons (Cγ, Cε, or Cα), thereby altering effector functions of the antibody molecule. This process depends on, and is orchestrated by, activation-induced deaminase (AID), a DNA cytidine deaminase that acts on single-stranded DNA exposed during transcription of switch (S) region sequences at the IgH locus. DNA lesions thus generated are processed by components of several general DNA repair pathways to drive CSR. Given that AID can instigate DNA lesions and genomic instability, stringent checks are imposed that constrain and restrict its mutagenic potential. In this review, we will discuss how AID expression and substrate specificity and activity is rigorously enforced at the transcriptional, post-transcriptional, post-translational, and epigenetic levels, and how the DNA-damage response is choreographed with precision to permit targeted activity while limiting bystander catastrophe.
    Full-text · Article · Mar 2014 · Frontiers in Immunology
  • Source
    • "This ensures high AID expression only in activated B cells with appropriate signals, as occurring within GCs upon interaction with follicular dendritic cells and T follicular helper cells. In addition, AID can appear at low levels in some bone marrow developing B cells upon stimulation of toll like receptors (TLR) [7, 8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Survival and phenotype of normal and malignant B lymphocytes are critically dependent on constitutive signals by the B cell receptor (BCR) for antigen. In addition, either antigen ligation of the BCR or various mitogenic stimuli result in B cell activation and induction of activation-induced deaminase (AID). AID activity can in turn mediate somatic hypermutation (SHM) of immunoglobulin (Ig) V regions and also deeply remodel the Ig heavy chain locus through class switch recombination (CSR) or locus suicide recombination (LSR). In addition to changes linked to affinity for antigen, modifying the class/isotype (i.e. the structure and function) of the BCR or suddenly deleting BCR expression also modulates the fate of antigen-experienced B cells.
    Full-text · Article · Mar 2014 · Oncotarget
  • Source
    • "T1 was somewhat higher compared with B6 T1 cells, but differences were not statistically significant (Fig. 4 F). Importantly, consistent with Ueda et al. (2007) and Han et al. (2007), T1 cells were the only B cell subset with measurable levels of Aicda mRNA, suggesting that unstimulated T1 cells have the capacity to produce class­switched Abs. Further analysis of TLR7.1Tg and WT T1, T2, FO, and MZ B cells revealed that TLR7.1Tg "
    [Show abstract] [Hide abstract]
    ABSTRACT: Toll-like receptor (TLR), a ligand for single-stranded RNA, has been implicated in the development of pathogenic anti-RNA autoantibodies both in systemic lupus erythematous (SLE) patients and in murine models of lupus. It is still unclear, however, where and how TLR7-mediated interactions affect the development of autoreactive B cells. We found that overexpression of TLR7 in transgenic mice (TLR7.1Tg) leads to marked alterations of transitional (T1) B cells, associated with their expansion and proliferation within the splenic red pulp (RP). This phenotype was intrinsic to the T1 subset of B cells and occurred independently of type 1 IFN signals. Overexpression of RNase in TLR7.1Tg mice significantly limited the expansion and proliferation of T1 cells, indicating that endogenous RNA complexes are driving their activation. TLR7.1Tg T1 cells were hyper-responsive to anti-IgM and TLR7 ligand stimulation in vitro and produced high concentrations of class-switched IgG2b and IgG2c, including anti-RNA antibodies. Our results demonstrate that initial TLR7 stimulation of B cells occurs at the T1 stage of differentiation in the splenic RP and suggest that dysregulation of TLR7 expression in T1 cells can result in production of autoantibodies.
    Full-text · Article · Oct 2013 · Journal of Experimental Medicine
Show more